Hexa Tradex Ltd
HEXATRADEXHexa Tradex Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 73rd percentile of its own range — the multiple has already done part of the work.
The price is in a downtrend (82 weeks in) while the P/E sits at the 73rd percentile of its own 10-year range. Underneath, the last four quarters read mixed, and 62% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Hexa Tradex Ltd trades at ₹156, in a downtrend and 82 weeks into that stage. That is −5.3% against its own 200-day average. It sits at 4% of a 52-week range of ₹155 to ₹175. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (20 weeks and counting).
Today the stock is in a downtrend — week 82 of stage 4, confirmed. At ₹156 it trades −5.3% versus its 200-day average and sits at 4% of its 52-week range (₹155–₹175).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +922% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (20 weeks and counting; last ahead the week of 2026-05-29) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Hexa Tradex Ltd trades at 40.5× P/E, at the pricey end of its own range (73rd percentile). Its long-run median P/E is 10.3×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 40.5× is at the pricey end of its own range (73rd percentile), against a long-run median of 10.3× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 10y, of the +23.6%/yr price move, ~+5.0%/yr came from earnings growth and ~+18.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Hexa Tradex Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −1.5% | +72.1% | +69.1% | −11.8% |
| Share price | −12.0% | +2.3% | −4.4% | +23.6% |
4-Factor Sector Score
40.3/100 — rank 29 of 52 in Trading · 65% evidence confidence
Hexa Tradex Ltd scores 40.3 out of 100 against the 52 companies it is compared with in Trading, ranking 29. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.2 + 6.1 + 10 + 7 = 40.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Hexa Tradex Ltd reported ₹0.0 Cr of revenue in the Jun 26 quarter. Over 10 years it has compounded at −11.8% a year. The last full year, FY26, came in at ₹5.4 Cr. The last four reported quarters add to ₹4.6 Cr.
FY26 revenue came in at ₹5.4 Cr (−1.5% on the year), capping 10 years at −11.8% compound. The latest quarter (Jun 26) printed ₹0.0 Cr, null year on year.
Pace check: the last four quarters averaged −0.8% growth against the decade's −11.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.4% over the last 4 quarters against −66.4%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A clean operating margin is not in our numbers for Hexa Tradex Ltd — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.
This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for Hexa Tradex Ltd.
🚨 Why the margin moved: operating margin went −268.8 pp year on year while gross margin went +0.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Hexa Tradex Ltd earned ₹1.7 Cr of net profit in the Jun 26 quarter. The full FY26 year was a loss of ₹8.7 Cr. The same quarter a year earlier lost ₹0.2 Cr. 8 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹1.7 Cr, null year on year. On the full year, FY26 printed ₹−8.7 Cr (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 62% of Hexa Tradex Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹−3.6 Cr of operating cash against ₹−8.7 Cr of profit. After ₹0.0 Cr of capital spending, ₹−4.0 Cr was left as free cash.
FY26: operating cash of ₹−3.6 Cr against reported profit of ₹−8.7 Cr, leaving free cash of ₹−4.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 62% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 62%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Hexa Tradex Ltd's cash conversion cycle runs 0 days in FY26, down from 0 days in FY21. Capital spending ran ₹0.0 Cr over the last 3 years. At FY26 sales of ₹5.4 Cr each day of that cycle holds about ₹0.0 Cr, so roughly ₹0.0 Cr sits inside the business at any moment.
FY26: debtors at 0 days (an asset-light business — no inventory to speak of) — for a full cycle of 0 days, tighter than FY21's 0.
In money terms: at FY26 sales of ₹5.4 Cr, each day of the cycle holds about ₹0.0 Cr — so the 0-day loop keeps roughly ₹0.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹0.0 Cr over the last 3 fiscal years. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Hexa Tradex Ltd earns a ROCE of −0% in FY26. That is up from a trough of −16% in FY18. Return on invested capital clears the cost of that capital by −11.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −161.5% net margin on 0.00× asset turns.
FY26 ROCE is −0%, recovered from a FY18 trough of −16% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): −161.5% net margin × 0.00× asset turns × 1.15× balance-sheet leverage ≈ 0.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 0.1% − 12.0% = a −11.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Hexa Tradex Ltd carries total debt of ₹9.0 Cr against shareholder equity of ₹4,616 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.21 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹9.0 Cr against shareholder equity of ₹4,616 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.21 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Hexa Tradex Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.0 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.0 points over 8 quarters to 92.1%; Foreign institutions: +0.0 points over 8 quarters to 0.1%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Hexa Tradex Ltd: the Z-score reads 0.82. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 0.82 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 0.82.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Onix Solar Energy LtdONIXSOLAR | 70.9/100Favorable setup69% evidence | 28.9/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 18.3/25 ROCE 32% · OPM 30% 76% evidence | 10.3/20 P/E 24.4× · PEG — 15% evidence | 13.4/20 RS sector 68.4% · RS bench -3.5% · 1Y 49.1%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 28.9 + 18.3 + 10.3 + 13.4 = 70.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Rashi Peripherals LtdRPTECH | 69.0/100Favorable setup75% evidence | LEADER | 24.9/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.7/20 P/E 17.1× · PEG — 15% evidence | 18.7/20 RS sector 51.6% · RS bench 69.1% · 1Y 176.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 14.7 + 10.7 + 18.7 = 69 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Nupur Recyclers LtdNRL | 67.9/100Favorable setup87% evidence | LEADER | 22.5/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.5/25 ROCE 15.1% · OPM 11.6% 95% evidence | 9.2/20 P/E 53.6× · PEG — 50% evidence | 19.7/20 RS sector 66.4% · RS bench 88.4% · 1Y 89.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.5 + 9.2 + 19.7 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Magnus Steel & Infra Ltd517320 | 67.5/100Thin evidence · provisional56% evidence | 27.8/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1449.6%0 of 1 week ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.8 + 18.5 + 9.2 + 12 = 67.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Vision Infra Equipment Solutions LtdVIESL | 67.3/100Thin evidence · provisional56% evidence | TURNING | 19.0/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.8/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 14.9× · PEG — 15% evidence | 17.6/20 RS sector 26.9% · RS bench 44.5% · 1Y 122.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 10.9 + 17.6 = 67.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Shankara Buildpro LtdBUILDPRO | 63.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.6/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.3/25 ROCE 39% · OPM 3.2% 100% evidence | 10.4/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 25.6 + 17.3 + 10.4 + 10 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Ivalue Infosolutions LtdIVALUE | 60.4/100Mixed-positive evidence60% evidence | ASLEEP | 20.6/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.4%6 of 10 weeks ahead 0% evidence |
| Exact sum: 20.6 + 18.6 + 11.2 + 10 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sudarshan Pharma Industries Ltd543828 | 60.3/100Mixed-positive evidence82% evidence | LEADER | 20.9/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.6/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.9/20 P/E 39.2× · PEG — 50% evidence | 16.9/20 RS sector 17.5% · RS bench 33.4% · 1Y 25.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.6 + 8.9 + 16.9 = 60.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Euro Pratik Sales LtdEUROPRATIK | 59.9/100Mixed-positive evidence73% evidence | ASLEEP | 15.1/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.5/25 ROCE 38.4% · OPM 26% 100% evidence | 15.3/20 P/E 29.1× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y 4.7%6 of 10 weeks ahead 0% evidence |
| Exact sum: 15.1 + 19.5 + 15.3 + 10 = 59.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 10Tembo Global Industries LtdTEMBO | 59.0/100Mixed-positive evidence80% evidence | TURNING | 22.2/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.4/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.2× · PEG — 15% evidence | 7.1/20 RS sector -17.4% · RS bench -4.5% · 1Y -10.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 18.4 + 11.3 + 7.1 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Mangalam Global Enterprise LtdMGEL | 58.7/100Mixed-positive evidence80% evidence | 25.7/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.8/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 6.1/20 RS sector -14.5% · RS bench -0.2% · 1Y -3.5%6 of 7 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.7 + 15.8 + 11.1 + 6.1 = 58.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -3.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Arisinfra Solutions LtdARIS | 57.6/100Mixed-positive evidence65% evidence | TURNING | 22.0/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.1/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 9.7/20 RS sector — · RS bench -1.2% · 1Y -12.3%4 of 10 weeks ahead 25% evidence |
| Exact sum: 22 + 15.1 + 10.8 + 9.7 = 57.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.4/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.2/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.2/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 245× · PEG — 15% evidence | 13.1/20 RS sector -1.1% · RS bench 13.5% · 1Y 29.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 13.2 + 8.9 + 13.1 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Patel Retail LtdPATELRMART | 53.8/100Mixed-positive evidence65% evidence | ASLEEP | 18.1/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.8/20 P/E 16.9× · PEG — 15% evidence | 10.6/20 RS sector — · RS bench 2.8% · 1Y -18.4%5 of 10 weeks ahead 25% evidence |
| Exact sum: 18.1 + 14.3 + 10.8 + 10.6 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Prostarm Info Systems LtdPROSTARM | 52.0/100Mixed-positive evidence65% evidence | BASING | 17.1/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.1/25 ROCE 18% · OPM 8.5% 95% evidence | 10.5/20 P/E 22× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -12.2% · 1Y -35.5%0 of 10 weeks ahead 25% evidence |
| Exact sum: 17.1 + 16.1 + 10.5 + 8.3 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Fabtech Technologies LtdFABTECH | 50.8/100Thin evidence · provisional52% evidence | TURNING | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.3/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.3 + 11 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Lloyds Enterprises LtdLLOYDSENT | 50.3/100Mixed-positive evidence75% evidence | TURNING | 18.1/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.3/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 93.3× · PEG — 15% evidence | 11.8/20 RS sector -5% · RS bench 8.7% · 1Y -6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 11.3 + 9.1 + 11.8 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18BMW Ventures LtdBMW | 50.0/100Thin evidence · provisional55% evidence | 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 11.9/25 ROCE 12% · OPM 3.4% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead 0% evidence | |
| Exact sum: 16.9 + 11.9 + 11.2 + 10 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19SG Mart LtdSGMART | 48.9/100Mixed-negative evidence93% evidence | LEADER | 13.9/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.6/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 76.1× · PEG 1.92 65% evidence | 18.2/20 RS sector 34.9% · RS bench 51.7% · 1Y 106.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 8.6 + 8.2 + 18.2 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 51.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Bizotic Commercial Ltd543926 | 48.7/100Thin evidence · provisional58% evidence | BASING | 19.8/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.6/25 ROCE 26.8% · OPM 8% 76% evidence | 9.7/20 P/E 34.1× · PEG — 50% evidence | 0.6/20 RS sector -86.7% · RS bench -18.3% · 1Y -72.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 18.6 + 9.7 + 0.6 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Yogi LtdYOGI | 47.9/100Thin evidence · provisional58% evidence | 20.3/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 9.9/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.5/20 P/E 54.1× · PEG — 15% evidence | 8.2/20 RS sector -6.5% · RS bench -2.1% · 1Y -11.1%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.3 + 9.9 + 9.5 + 8.2 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Shiv Aum Steels LtdSHIVAUM | 47.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.9/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.2/20 P/E 66.8× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 38.3% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 16.9 + 11.4 + 7.2 + 11.9 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Dhunseri Ventures LtdDVL | 46.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.6/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.7/25 ROCE 6.7% · OPM 39% 95% evidence | 11.9/20 P/E 5.3× · PEG — 50% evidence | 12.6/20 RS sector -7.1% · RS bench 8% · 1Y -14.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.7 + 11.9 + 12.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Adani Enterprises LtdADANIENT | 45.5/100Mixed-negative evidence93% evidence | TURNING | 14.3/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.5/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 174× · PEG 1.96 65% evidence | 15.0/20 RS sector 8.6% · RS bench 23.9% · 1Y 38.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 8.5 + 7.7 + 15 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25MMTC LtdMMTC | 44.8/100Mixed-negative evidence96% evidence | ASLEEP | 15.1/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 8.0/25 ROCE 8.7% · OPM — 84% evidence | 15.3/20 P/E 46.1× · PEG 0.92 100% evidence | 6.4/20 RS sector -14.9% · RS bench -1.9% · 1Y -4.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 8 + 15.3 + 6.4 = 44.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 26State Trading Corporation of India LtdSTCINDIA | 42.5/100Mixed-negative evidence67% evidence | ASLEEP | 19.6/35 Revenue — · PAT 100% · OPM change -14.6 pp 67% evidence | 5.6/25 ROCE -0.9% · OPM — 80% evidence | 11.9/20 P/E 14× · PEG — 50% evidence | 5.4/20 RS sector -28.7% · RS bench -5.6% · 1Y -5.6%2 of 11 weeks ahead 70% evidence |
| Exact sum: 19.6 + 5.6 + 11.9 + 5.4 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27RRP Semiconductor LtdRRP | 41.1/100Thin evidence · provisional54% evidence | 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.4/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.3/20 RS sector 65.3% · RS bench 0.8% · 1Y 66.5%0 of 1 week ahead 70% evidence | |
| Exact sum: 11.4 + 5.4 + 10 + 14.3 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Cropster Agro Ltd523105 | 40.7/100Mixed-negative evidence65% evidence | 16.0/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.3/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.1/20 P/E 31× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -62.7% · 1Y -83.2%0 of 1 week ahead to 2026-08-09 70% evidence | |
| Exact sum: 16 + 11.3 + 10.1 + 3.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Hexa Tradex Ltdthis pageHEXATRADEX | 40.3/100Mixed-negative evidence65% evidence | BASING | 17.2/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.1/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.0/20 RS sector -16.8% · RS bench -3.7% · 1Y -12.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 6.1 + 10 + 7 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Hardwyn India LtdHARDWYN | 40.2/100Mixed-negative evidence87% evidence | ASLEEP | 13.8/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.5/25 ROCE 4.8% · OPM 13% 95% evidence | 12.1/20 P/E 50.6× · PEG — 50% evidence | 1.8/20 RS sector -38.3% · RS bench -29.5% · 1Y -3.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 12.5 + 12.1 + 1.8 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Blue Pearl Agriventures LtdBPAGRI | 39.8/100Mixed-negative evidence69% evidence | 20.5/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.3/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -91.2%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.5 + 6.3 + 8.7 + 4.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Pervasive Commodities Ltd517172 | 38.3/100Thin evidence · provisional52% evidence | 12.7/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 5.6/25 ROCE 0% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 12.7 + 5.6 + 10 + 10 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Riddhi Siddhi Gluco Biols Ltd524480 | 38.0/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.6/25 ROCE 2.7% · OPM -3% 76% evidence | 6.5/20 P/E 37.3× · PEG — 50% evidence | 12.5/20 RS sector 10.5% · RS bench 25.4% · 1Y 33.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.6 + 6.5 + 12.5 = 38 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34PTC India LtdPTC | 36.6/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.6/25 ROCE 13.4% · OPM 3.1% 76% evidence | 9.7/20 P/E 8.8× · PEG — 50% evidence | 3.1/20 RS sector -21.6% · RS bench -9.8% · 1Y -13%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.6 + 9.7 + 3.1 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Neueon Corporation LtdNEUEON | 35.6/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.7/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.8/20 RS sector 12.7% · RS bench -1.5% · 1Y —1 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.7 + 10 + 12.8 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Kothari Industrial Corporation LtdKOTIC | 34.2/100Adverse evidence63% evidence | BASING | 18.8/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.6/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -58.6% · RS bench -43.5% · 1Y -77.5%0 of 9 weeks ahead 70% evidence |
| Exact sum: 18.8 + 1.6 + 10 + 3.8 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Shanti Overseas (India) LtdSHANTI | 32.3/100Thin evidence · provisional56% evidence | 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.1/20 P/E 3× · PEG — 50% evidence | 3.5/20 RS sector -60.4% · RS bench -49.7% · 1Y -47.1%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.2 + 4.5 + 13.1 + 3.5 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38BN Agrochem LtdBNAGROCHEM | 32.2/100Adverse evidence77% evidence | ASLEEP | 12.9/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.4/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 117× · PEG — 15% evidence | 5.9/20 RS sector -16.7% · RS bench -35.6% · 1Y -46.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.9 + 4.4 + 9 + 5.9 = 32.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Uniphos Enterprises LtdUNIENTER | 30.4/100Adverse evidence69% evidence | BASING | 12.6/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.6/25 ROCE 0.8% · OPM — 80% evidence | 8.8/20 P/E 31.4× · PEG — 50% evidence | 4.4/20 RS sector -43.6% · RS bench -22% · 1Y -41%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 4.6 + 8.8 + 4.4 = 30.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | 2.8/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.8/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -32% · 1Y -49.6%0 of 6 weeks ahead to 2026-08-16 70% evidence | |
| Exact sum: 2.8 + 7.8 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Mardia Samyoung Capillary Tubes Company LtdMSCTC | 56.9/100Thin evidence · provisional32% evidence | 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 74.6% · 1Y 93.7%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.8 + 15.2 + 8.6 + 12.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Proventus Agrocom LtdPROV | 56.7/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.4/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.1/20 P/E 42.8× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 26.9% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.4 + 13.1 + 11.6 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43DC Infotech & Communication LtdDCI | 56.3/100Thin evidence · provisional35% evidence | 18.6/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.6/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 9.5/20 RS sector — · RS bench -1.6% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 17.6 + 10.6 + 9.5 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44SK Minerals & Additives Ltd544584 | 55.8/100Thin evidence · provisional36% evidence | TURNING | 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.0/25 ROCE 26.2% · OPM 10.7% 76% evidence | 10.2/20 P/E 29.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 4 weeks ahead 0% evidence |
| Exact sum: 16.6 + 19 + 10.2 + 10 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Monika Alcobev LtdMONIKA | 54.0/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -10.9%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.6 + 10 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Shah Foods Ltd519031 | 53.6/100Thin evidence · provisional18% evidence | TURNING | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.8/20 P/E 276× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 103.9% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.8 + 12.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Pramara Promotions LtdPRAMARA | 51.7/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 13.9/25 ROCE 15.2% · OPM 15% 71% evidence | 6.9/20 P/E 51.3× · PEG — 50% evidence | 14.3/20 RS sector 7.9% · RS bench 29% · 1Y 34.5%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 13.9 + 6.9 + 14.3 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Manbro Industries Ltd512595 | 50.9/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.1/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 62.6%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.1 + 10 + 9.5 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Le Merite Exports LtdLEMERITE | 47.2/100Thin evidence · provisional40% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.1/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 9.9/20 RS sector -9% · RS bench 15% · 1Y 28.1%2 of 12 weeks ahead to 2026-05-17 70% evidence | |
| Exact sum: 18.9 + 9.1 + 9.3 + 9.9 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Satani Bearings Ltd505703 | 45.2/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5197× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 24.9% · 1Y 176.6%1 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Keto Motors Ltd537392 | 43.3/100Thin evidence · provisional38% evidence | TURNING | 16.3/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 7503× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 272.8% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 16.3 + 6 + 8.5 + 12.5 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52A-1 LtdA1L | 41.0/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.3/20 RS sector -24.5% · RS bench -16% · 1Y -8.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 10.7 + 8.8 + 5.3 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Hexa Tradex Ltd's share price today?
Hexa Tradex Ltd trades at ₹156, −12.0% over the past year. The company is valued at ₹861 Cr. The stock sits at 4% of its 52-week range of ₹155–₹175, −5.3% versus its 200-day average. On the tape, the price is in a downtrend, 82 weeks in. — as of 11 September 2026.
What were Hexa Tradex Ltd's latest quarterly results?
Hexa Tradex Ltd reported revenue of ₹0.0 Cr and net profit of ₹1.7 Cr for the Jun 26 quarter. Earnings per share were ₹0.30. — as of 11 September 2026.
What is Hexa Tradex Ltd's revenue?
Hexa Tradex Ltd reported revenue of ₹0.0 Cr in the Jun 26 quarter. For the full FY26 fiscal year, revenue was ₹5.4 Cr (−1.5%). Over the last 10 years revenue compounded at −11.8% a year. — as of 11 September 2026.
What is Hexa Tradex Ltd's profit?
Hexa Tradex Ltd earned ₹1.7 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹−8.7 Cr. — as of 11 September 2026.
What is Hexa Tradex Ltd's market cap?
Hexa Tradex Ltd's market capitalisation is ₹861 Cr at a share price of ₹156. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Hexa Tradex Ltd's P/E ratio?
Hexa Tradex Ltd trades at a P/E of 40.5×, at the 73rd percentile of its own 10-year range, against a long-run median of 10.3×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Hexa Tradex Ltd pay a dividend?
No — Hexa Tradex Ltd has recorded a dividend payout of 0% of profit in each of its last 13 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is Hexa Tradex Ltd overvalued?
On its own history, Hexa Tradex Ltd looks expensive: its P/E of 40.5× sits at the 73rd percentile of its 10-year range (long-run median 10.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
How is Hexa Tradex Ltd performing?
Hexa Tradex Ltd is in a downtrend, 82 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 20 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Hexa Tradex Ltd in an uptrend?
No — the price is in a downtrend (week 82 of stage 4), trading −5.3% versus its 200-day average and at 4% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Hexa Tradex Ltd beating the market?
Not lately — on a trailing-13-week view Hexa Tradex Ltd is currently behind the NIFTY 500 (20 weeks and counting; last ahead the week of 2026-05-29), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +922% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Hexa Tradex Ltd's share price go up?
This page publishes no price forecast for Hexa Tradex Ltd. What it measures instead: the share price is ₹156, the price is in a downtrend 82 weeks in. Its P/E of 40.5× sits at the 73rd percentile of its own 10-year range. — as of 11 September 2026.
Who owns Hexa Tradex Ltd?
Promoters hold 92.1% of Hexa Tradex Ltd, foreign institutions 0.1%, domestic institutions 0.0% and the public 7.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Hexa Tradex Ltd have too much debt?
No — Hexa Tradex Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill −3×. FY26 borrowings were ₹8.6 Cr against equity of ₹4,616 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Hexa Tradex Ltd's capex?
Hexa Tradex Ltd spent ₹0.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹0.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Hexa Tradex Ltd's cash flow?
Hexa Tradex Ltd consumed ₹3.6 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−4.0 Cr). Reported profit that year was ₹−8.7 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Hexa Tradex Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 62% of Hexa Tradex Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−3.6 Cr against reported profit of ₹−8.7 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
How financially safe is Hexa Tradex Ltd?
On the balance sheet, the Z-score reads 0.82 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 11 September 2026.
Where is Hexa Tradex Ltd in its business cycle?
Hexa Tradex Ltd's FY26 operating margin was −104.3%, against a 13-year band of −18,466.7%–97.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Hexa Tradex Ltd story?
Biggest watch item: the P/E sits at the 73rd percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Hexa Tradex Ltd a stock worth studying right now?
This is not investment advice. The machine read: Hexa Tradex Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!